Resources Repository
-
ArticlePublication 2016Health, Financial and Distributional Consequences of Tobacco Excise Tax in Lebanon
This paper considers the financial and health effects, by socio-economic class, of increasing tobacco taxes …
This paper considers the financial and health effects, by socio-economic class, of increasing tobacco taxes in Lebanon, a middle-income country. Extended cost-effectiveness analysis (ECEA) methods are applied to quantify, across quintiles of socio-economic status, the health benefits gained, the additional tax revenues raised, and the net financial consequences for households from a 50% increase in the price of tobacco through excise taxes. The increase in tobacco tax is estimated to result in 65,000 premature deaths…
Cost-Effectiveness Analysis | Costing Methods | Chronic Disease/Risk | Policy/Regulation | Health/Medicine | Middle East & North Africa -
ArticlePublication 2016Country-Level Cost-Effectiveness Thresholds
This article estimates the cost-effectiveness thresholds (CETs) for health interventions in several low and middle-income …
This article estimates the cost-effectiveness thresholds (CETs) for health interventions in several low and middle-income countries (LMICs), based on opportunity costs. When there are constraints on a health care system’s budget or ability to increase expenditures, additional costs imposed by interventions have an “opportunity cost” in terms of the health foregone because other interventions cannot be provided. The authors argue that cost-effectiveness thresholds should reflect health opportunity cost and aim to calculate these in four…
Cost-Effectiveness Analysis | Priority Setting/Ethics | Health Systems | Economics/Finance | Health/Medicine | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Europe | Asia & Pacific -
ArticlePublication 2016Cost-Effectiveness of Routine Vaccination With a Live-Attenuated Dengue Vaccine: Model Comparison
Large Phase III trials across Asia and Latin America have demonstrated the efficacy of a recombinant, …
Large Phase III trials across Asia and Latin America have demonstrated the efficacy of a recombinant, live-attenuated dengue vaccine (Dengvaxia) over the first 25 months following vaccination. Subsequent data collected in the longer-term follow-up phase, however, have raised concerns about a potential increase in hospitalization risk of subsequent dengue infections, in particular among young, dengue-naïve vaccinees. This paper reports predictions from eight independent modelling groups on the long-term safety, public health impact, and cost-effectiveness of routine…
Cost-Effectiveness Analysis | Mathematical Models | Dynamic Transmission | Infectious Diseases | Child/Nutrition | Health Systems | Global Governance | Climate/Environment | Economics/Finance | Health/Medicine | Latin America & Caribbean | Asia & Pacific -
ArticlePublication 2016Cost-Effectiveness Thresholds: Pros and Cons
This WHO bulletin compares the two main methods for comparing the cost-effectiveness of health interventions. …
This WHO bulletin compares the two main methods for comparing the cost-effectiveness of health interventions. Cost-effectiveness thresholds allow health decision makers to identify cost-effectiveness ratios that represent good or bad value for money. In 2001, the World Health Organization's Commission on Macroeconomics in Health suggested cost-effectiveness thresholds based on multiples of a country's per-capita gross domestic product (GDP). In some contexts, these thresholds have been used as decision rules. However, this approach lacks country specificity…
Cost-Effectiveness Analysis | Priority Setting/Ethics | Health Systems | Health/Medicine -
ArticlePublication 2016Cost-Effectiveness of Hypertension Treatment According to 2014 Guidelines
This article compared the cost-effectiveness of hypertension treatment in non-Hispanic blacks and non-Hispanic whites according …
This article compared the cost-effectiveness of hypertension treatment in non-Hispanic blacks and non-Hispanic whites according to 2014 US hypertension treatment guidelines. The cardiovascular disease (CVD) policy model was used to simulate CVD events, quality-adjusted life years (QALYs), and treatment costs in 35- to 74-year-old adults with untreated hypertension. CVD incidence, mortality, and risk factor levels were obtained from cohort studies, hospital registries, vital statistics, and national surveys. The authors assumed a willingness-to-pay for health of…
Cost-Effectiveness Analysis | Microsimulation | Chronic Disease/Risk | Health/Medicine | North America -
ArticlePublication 2016Cost-Effectiveness of Intensive Blood Pressure Management
This article aimed to evaluate the cost-effectiveness of intensive blood pressure management compared with standard …
This article aimed to evaluate the cost-effectiveness of intensive blood pressure management compared with standard management among 68-year-old high-risk adults with hypertension but not diabetes. A Markov cohort model was developed to estimate lifetime costs and quality-adjusted life-years (QALYs) discounted at 3% annually. The Systolic Blood Pressure Intervention Trial (SPRINT) was used to estimate treatment effects and adverse event rates. The authors used Centers for Disease Control and Prevention Life Tables to project age- and…
Cost-Effectiveness Analysis | State-Transition | Chronic Disease/Risk | Health/Medicine | North America -
ArticlePublication 2016Cost-Effectiveness of Blood Pressure Treatment Guidelines in Adults 35-74
In this article the authors used the CVD Policy Model to compare the cost-effectiveness of …
In this article the authors used the CVD Policy Model to compare the cost-effectiveness of conservative versus intensive blood pressure treatment guidelines in adult hypertensive patients aged 35 to 74 years. Outcomes included in the study were CVD events, treatment costs, quality-adjusted life years, and drug and monitoring costs projected over the years 2016 to 2026. The effectiveness and costs of hypertension were calculated for treatment according to the 2003 Joint National Committee (JNC)-7 or…
Cost-Effectiveness Analysis | Microsimulation | Chronic Disease/Risk | Clinical Care | Health/Medicine | North America -
ArticlePublication 2016Health Gains & Financial Protection from Ethiopian Mental Health Strategy: An ECEA
Using the extended cost-effectiveness analysis (ECEA), this paper evaluates the impacts of fully publicly financed …
Using the extended cost-effectiveness analysis (ECEA), this paper evaluates the impacts of fully publicly financed care for depression, bipolar disorder, schizophrenia and epilepsy as part of the mental and neurological package (MN) of the National Mental Health Strategy in Ethiopia. The following outcomes were estimated disaggregated across wealth quintiles: (1) healthy-life-years (HALYs) gained; (2) household out-of-pocket (OOP) expenditures averted (3) expected financial risk protection (FRP); and (4) productivity impact. The MN package is expected to…
Cost-Effectiveness Analysis | Costing Methods | Health Outcomes | Mental Health | Economics/Finance | Health/Medicine | Sub-Saharan Africa -
ArticlePublication 2016Cost-Effectiveness of Collaborative Care for Depression and Comorbid Diabetes or CVD
This article, published in BMJ Open, presents an economic model that combines a decision tree …
This article, published in BMJ Open, presents an economic model that combines a decision tree and a Markov cohort model to investigate the long-term cost-effectiveness of collaborative care versus usual care for individuals with depression and comorbid diabetes and/or cardiovascular disease. Data from the COINCIDE trial informs the model input parameters. The COINCIDE trial is a randomized controlled trial of collaborative care versus usual care that enrolled 387 participants from 36 primary care general practices…
Cost-Effectiveness Analysis | State-Transition | Chronic Disease/Risk | Mental Health | Health/Medicine | Europe